Do Newcomers Cimzia and Simponi Pose a Threat to Established TNF-alpha Inhibitors in the Rheumatoid Arthritis Market?

— A Pharmacor Analyst Call from Decision Resources

As a purchaser of our 2009 Pharmacor Rheumatoid Arthritis report, Decision Resources is offering an exclusive analyst call entitled Do Newcomers Cimzia and Simponi Pose a Threat to Established TNF-alpha Inhibitors in the Rheumatoid Arthritis Market? Because this analyst call will feature report findings, it is ONLY available to purchasers of this report.

Please contact us to learn how you can purchase this report and attend the analyst call.

In a recent Decision Resources survey, 100 rheumatologists were asked to estimate their current and future use of the recently launched TNF-alpha inhibitors, UCB’s Cimzia and Centocor Ortho Biotech’s Simponi for the treatment of rheumatoid arthritis. The survey results suggest that Cimzia has gained favor among rheumatologists since its launch in April 2009, while the intravenous formulation of Simponi may struggle to secure a substantial share of the rheumatoid arthritis market. Over the next decade, established TNF-alpha inhibitors such as Amgen/Pfizer’s Enbrel, Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe’s Remicade and Abbott’s Humira are expected to lose market share to Cimzia and Simponi.

In this 15-minute analyst call, Decision Resources Director Cynthia Mundy, Ph.D. will answer the following questions:

• How do rheumatologists expect to use Cimzia and Simponi? How have their views evolved now that these agents have been marketed in the United States for six months?
• How will their positions in the treatment sequence impact the sales of Cimzia and Simponi through 2018?
• Among the established TNF-alpha inhibitors – Enbrel, Remicade and Humira – which are most at risk of losing share to Cimzia and Simponi?

Dr. Mundy will conduct a live Q & A session after the presentation.

Registration

Do Newcomers Cimzia and Simponi Pose a Threat to Established TNF-alpha Inhibitors in the Rheumatoid Arthritis Market?

November 10, 2009 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).

To learn how you can purchase this Pharmacor report and attend the analyst call, please contact us using the information below.

Contact Us

In North America — Steve Silvestro at 781-296-2626 or ssilvestro@dresources.com

In Europe — Kaj van Langendonck at +32-2-357-06-14 or kvanlangendonck@decisionresources.be

In Japan — Makiko Yoshimoto at +81-3-5401-2615 or makiko@dresources.jp

Terms of Use | Privacy Policy | Contact Us | Careers

Decision Resources • 260 Charles Street • Waltham, MA 02453

Register to receive our latest offers. You are receiving this email because you have previously requested information from Decision Resources.

© 2009 Decision Resources, Inc. All rights reserved.